After their treatment with LiAlH4 and then alcohol, new iron dicarbonyl complexes mer-trans-[Fe(Br)(CO)2(P-CH═N-P')][BF4] (where P-CH═N-P' = R2PCH2CH═NCH2CH2PPh2 and R = Cy or iPr or P-CH═N-P' = (S,S)- Cy2PCH2CH═NCH(Me)CH(Ph)PPh2) are catalysts for the hydrogenation of ketones in THF solvent with added KOtBu at 50 °C and 5 atm H2. Complexes with R = Ph are not active. With the enantiopure complex, alcohols are produced with an enantiomeric excess of up to 85% (S) at TOF up to 2000 h(-1), TON of up to 5000, for a range of ketones. An activated imine is hydrogenated to the amine in 90% ee at a TOF 20 h(-1)and TON 99. This is a significant advance in asymmetric pressure hydrogenation using iron. The complexes are prepared in two steps: (1) a one-pot reaction of phosphonium dimers ([cyclo-(PR2CH2CH(OH)(-))2][Br]2), KOtBu, FeBr2, and Ph2PCH2CH2NH2 (or (S,S)-Ph2PCH(Ph)CH(Me)NH2 for the enantiopure complex) in THF under a CO atmosphere to produce the complexes cis- and trans-[Fe(Br)2(CO)(P-CH═N-P')]; (2) the reaction of these with AgBF4 under CO(g) to afford the dicarbonyl complexes in high yield (50-90%). NMR and DFT studies of the process of precatalyst activation show that the dicarbonyl complexes are converted first to hydride-aluminum hydride complexes where the imine of the P-CH═N-P' ligand is reduced to an amide [P-CH2N-P'](-) with aluminum hydrides still bound to the nitrogen. These hydride species react with alcohol to give monohydride amine iron compounds FeH(OR')(CO)(P-CH2NH-P'), R' = Me, CMe2Et as well as the iron(0) complex Fe(CO)2(P-CH2NH-P') under certain conditions.
No takes yet. Share an insight, caveat, or question.
Lagaditis et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: